Reported Reactions

Drugs

Product name as reported

Acetaminophen Tramadol Hydrochloride: adverse event reports filed with FDA

799 reports list it as a suspect or interacting product, 2007–2026.

799
reports as suspect product
0% of all reports · about 41 a year
208
reports, 12 months to June 2026
182 in the 12 months before
99%
marked serious by the reporter
57.4% across all reports
20.3%
record death among outcomes, as reported
162 reports · not verified by FDA

Between February 2007 and June 2026, 799 adverse event reports received by FDA list the product name "Acetaminophen Tramadol Hydrochloride" as reporters wrote it as a suspect or interacting product. Reports that mention it only as a concomitant medication (1,087) are left out of every figure here.

In the 12 months to June 2026, 208 reports listed it, up 14% from 182 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 41 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.

Reporters most often recorded off label use (34.7%), drug ineffective (32.9%) and nausea (29.2%). A report can list several reactions, so shares add to more than 100%; 528 different terms appear across these reports. Off label use is recorded in 34.7% of these reports, against 4.1% of all reports in the database.

99% of the reports are marked serious by the reporter; 20.3% record death among the outcomes and 41.6% record hospitalisation, as reported. 33.5% of the reports came from other health professionals, and the largest patient age group is 18 to 44 (27.2%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

01427Jul 2021: 4Aug 2021: 1Sep 2021: 3Oct 2021: 5Nov 2021: 7Dec 2021: 132022Jan 2022: 3Feb 2022: 5Mar 2022: 10Apr 2022: 9May 2022: 12Jun 2022: 7Jul 2022: 4Aug 2022: 16Sep 2022: 4Oct 2022: 15Nov 2022: 17Dec 2022: 72023Jan 2023: 18Feb 2023: 5Mar 2023: 8Apr 2023: 14May 2023: 11Jun 2023: 9Jul 2023: 7Aug 2023: 7Sep 2023: 19Oct 2023: 24Nov 2023: 4Dec 2023: 132024Jan 2024: 2Feb 2024: 11Mar 2024: 15Apr 2024: 12May 2024: 8Jun 2024: 7Jul 2024: 13Aug 2024: 14Sep 2024: 22Oct 2024: 24Nov 2024: 12Dec 2024: 212025Jan 2025: 13Feb 2025: 17Mar 2025: 10Apr 2025: 7May 2025: 6Jun 2025: 23Jul 2025: 21Aug 2025: 10Sep 2025: 11Oct 2025: 15Nov 2025: 16Dec 2025: 132026Jan 2026: 16Feb 2026: 23Mar 2026: 27Apr 2026: 14May 2026: 17Jun 2026: 25

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

0811622007: 120072008: 12011: 120112012: 32013: 220132015: 182017: 420172018: 22019: 1220192020: 152021: 4720212022: 1092023: 13920232024: 1612025: 16220252026: 122

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Acetaminophen Tramadol Hydrochloride reports recording the termall reports in the database

  1. Off label useused for a purpose or in a way not on the label34.7%277
  2. Drug ineffectivethe medicine did not work as expected32.9%263
  3. Nauseafeeling sick29.2%233
  4. Product use in unapproved indicationused for a purpose not on the label26.8%214
  5. Hyperhidrosisexcessive sweating20.7%165
  6. Sedationdrowsiness from a medicine20.5%164
  7. Nightmarenightmares19.3%154
  8. Dyspnoeashortness of breath18.8%150
  9. Vomitingbeing sick18.8%150
  10. Nephrolithiasiskidney stones16.5%132
  11. Painpain, site not specified15.1%121
  12. Drug intolerancethe medicine was not tolerated14.6%117
  13. Malaisegeneral feeling of being unwell14.6%117
  14. Headachehead pain14.5%116
  15. Condition aggravatedthe condition being treated got worse14.1%113
  16. Drug hypersensitivityan allergic-type reaction to a medicine13.1%105
  17. Hypertensionhigh blood pressure12.6%101
  18. Arthralgiajoint pain11.6%93
  19. Hypersensitivityan allergic-type reaction11.6%93
  20. Rheumatoid arthritisrheumatoid arthritis, an inflammatory joint disease11.5%92
  21. Wheezingwheezing11.4%91
  22. Joint swellinga swollen joint10.9%87
  23. Maternal exposure during pregnancythe mother took the medicine during pregnancy10.9%87
  24. Pneumonialung infection10.6%85
  25. Confusional stateconfusion10.5%84
  26. Hepatic enzyme increasedraised liver enzymes10.5%84
  27. Infusion related reactiona reaction during or soon after an infusion10.5%84
  28. Rashskin rash10.5%84

Top 30 of 528 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Death20.3%162
Life-threatening19.8%158
Hospitalisation (initial or prolonged)41.6%332
Disability16.6%133
Congenital anomaly16%128
Other serious83.9%670
Not serious1%8

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Patient age

Under 20%0
2 to 110.1%1
12 to 171%8
18 to 4427.2%217
45 to 6427%216
65 to 747.3%58
75 and over9.5%76
Age not given27.9%223

Patient sex

Female48.9%391
Male35.2%281
Not given15.9%127

Who reported

Physician33.3%266
Pharmacist8.4%67
Other health professional33.5%268
Lawyer1%8
Consumer or non-health professional23.2%185
Not given0.6%5

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 2.3% of reports give the United States as the country of the event or reporter.

Reason for use recorded

Indication as recorded (MedDRA)ReportsShare
Migraine14117.6%
Pain637.9%
Analgesic therapy192.4%
Foetal exposure during pregnancy182.3%
Back pain141.8%
Depression70.9%

The indication field is filled in by the reporter and is often blank; shares are of all 799 reports.

In context

MeasureAcetaminophen Tramadol HydrochlorideAll reports
Reports as suspect product79920,646,523
Share of that pool—0%
Reports, latest 12 months2081,332,454
Marked serious99%57.4%
Death recorded among outcomes, per 1,000 reports20391
Hospitalisation recorded, per 1,000 reports416213
Consumer-filed share23.2%45.8%
Top term, share of reportsOff label use 34.7%4.1%

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Questions about Acetaminophen Tramadol Hydrochloride reports

How many adverse event reports has FDA received for Acetaminophen Tramadol Hydrochloride?

799 reports list Acetaminophen Tramadol Hydrochloride as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 208 of them arrived in the latest 12 months. Another 1,087 list it only as a concomitant medication.

What reactions are recorded in Acetaminophen Tramadol Hydrochloride reports?

off label use (34.7%), drug ineffective (32.9%), nausea (29.2%), product use in unapproved indication (26.8%) and hyperhidrosis (20.7%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Acetaminophen Tramadol Hydrochloride was responsible.

How serious are the reports?

99% are marked serious by the reporter. Among the outcomes recorded, 20.3% of reports include death and 41.6% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.

Who files these reports?

other health professional (33.5%), physician (33.3%) and consumer or non-health professional (23.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.

Are reports for Acetaminophen Tramadol Hydrochloride rising?

208 reports in the 12 months to June 2026, up 14% from 182 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.

Do these reports show that Acetaminophen Tramadol Hydrochloride was responsible for these reactions?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.

Is this a list of the side effects of Acetaminophen Tramadol Hydrochloride?

No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.

How do I report an adverse event?

Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Acetaminophen Tramadol Hydrochloride as a suspect or interacting product; reports listing it only as a concomitant medication (1,087) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.